Brazil: Anvisa debates review of cannabis product regulation at Dicol meeting
Sechat
The meeting is scheduled for March 26, the proposed public consultation to review the regulation of cannabis products for medical use, updating RDC 327/2019
The Collegiate Board of Anvisa (Dicol) will analyze, on March 26, the proposal for a public consultation to review the regulation of cannabis products for medical use. The theme is on the agenda of the meeting, under the report of director Romison Rodrigues Mota.
The proposal seeks to update RDC 327/2019, which establishes the requirements for the manufacture, import and marketing of these products in Brazil. The revision of the standard can impact patient access and the regulated market, which has grown in recent years.
The meeting will be held at the Anvisa headquarters in Brasilia, and can be followed live by the agency’s website. Interested in speaking out on the topic should apply by March 21. Click here to access the agenda:
